Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 202

1.

Functional screen for secreted proteins by monoclonal antibody library and identification of Mac-2 Binding protein (Mac-2BP) as a potential therapeutic target and biomarker for lung cancer.

Sun L, Chen L, Sun L, Pan J, Yu L, Han L, Yang Z, Luo Y, Ran Y.

Mol Cell Proteomics. 2013 Feb;12(2):395-406. doi: 10.1074/mcp.M112.020784.

2.

Antibody library-based tumor endothelial cells surface proteomic functional screen reveals migration-stimulating factor as an anti-angiogenic target.

Hu H, Ran Y, Zhang Y, Zhou Z, Harris SJ, Yu L, Sun L, Pan J, Liu J, Lou J, Yang Z.

Mol Cell Proteomics. 2009 Apr;8(4):816-26. doi: 10.1074/mcp.M800331-MCP200.

3.

Dendritic cell-specific intercellular adhesion molecule 3-grabbing non-integrin (DC-SIGN) recognizes a novel ligand, Mac-2-binding protein, characteristically expressed on human colorectal carcinomas.

Nonaka M, Ma BY, Imaeda H, Kawabe K, Kawasaki N, Hodohara K, Kawasaki N, Andoh A, Fujiyama Y, Kawasaki T.

J Biol Chem. 2011 Jun 24;286(25):22403-13. doi: 10.1074/jbc.M110.215301.

4.

A new small cell lung cancer (SCLC)-specific marker discovered through antigenic subtraction of neuroblastoma cells.

Krueger P, Nitz C, Foster R, MacDonald C, Gelber O, Lalehzadeh G, Goodson R, Winter J, Gelber C.

Cancer Immunol Immunother. 2003 Jun;52(6):367-77.

PMID:
12669243
6.

Identification of ATP synthase beta subunit (ATPB) on the cell surface as a non-small cell lung cancer (NSCLC) associated antigen.

Lu ZJ, Song QF, Jiang SS, Song Q, Wang W, Zhang GH, Kan B, Chen LJ, Yang JL, Luo F, Qian ZY, Wei YQ, Gou LT.

BMC Cancer. 2009 Jan 14;9:16. doi: 10.1186/1471-2407-9-16.

7.

Up-regulation of Mac-2 binding protein by hTERT in gastric cancer.

Park YP, Choi SC, Kim JH, Song EY, Kim JW, Yoon DY, Yeom YI, Lim JS, Kim JW, Paik SG, Lee HG.

Int J Cancer. 2007 Feb 15;120(4):813-20.

8.

Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.

Sepiashvili L, Hui A, Ignatchenko V, Shi W, Su S, Xu W, Huang SH, O'Sullivan B, Waldron J, Irish JC, Perez-Ordonez B, Liu FF, Kislinger T.

Mol Cell Proteomics. 2012 Nov;11(11):1404-15. doi: 10.1074/mcp.M112.020933.

9.

Serum Mac-2BP does not distinguish men with high grade, large volume prostate cancer from men with benign prostatic hyperplasia.

Peehl DM, Chen Z, Nolley R.

Prostate. 2011 Jan 1;71(1):26-31. doi: 10.1002/pros.21218.

PMID:
20583127
10.

Combined use of oligonucleotide and tissue microarrays identifies cancer/testis antigens as biomarkers in lung carcinoma.

Sugita M, Geraci M, Gao B, Powell RL, Hirsch FR, Johnson G, Lapadat R, Gabrielson E, Bremnes R, Bunn PA, Franklin WA.

Cancer Res. 2002 Jul 15;62(14):3971-9.

11.
12.

Generation of monoclonal antibody MS17-57 targeting secreted alkaline phosphatase ectopically expressed on the surface of gastrointestinal cancer cells.

Li M, Gao J, Feng R, Wang Y, Chen X, Sun J, Zhang D, Zhu Z, Ellis LM, Lu M, Lee JE, Feng Z, Liu B.

PLoS One. 2013 Oct 15;8(10):e77398. doi: 10.1371/journal.pone.0077398.

13.

Identification of isocitrate dehydrogenase 1 as a potential diagnostic and prognostic biomarker for non-small cell lung cancer by proteomic analysis.

Tan F, Jiang Y, Sun N, Chen Z, Lv Y, Shao K, Li N, Qiu B, Gao Y, Li B, Tan X, Zhou F, Wang Z, Ding D, Wang J, Sun J, Hang J, Shi S, Feng X, He F, He J.

Mol Cell Proteomics. 2012 Feb;11(2):M111.008821. doi: 10.1074/mcp.M111.008821.

14.

[Preparation of monoclonal antibody against lung cancer and identification of its targeting antigen].

Lu Z, Song Q, Song Q, Jiang S, Yang J, Luo F.

Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2010 Feb;27(1):147-51. Chinese.

PMID:
20337043
15.

C10ORF97 is a novel tumor-suppressor gene of non-small-cell lung cancer and a functional variant of this gene increases the risk of non-small-cell lung cancer.

Shi Y, Chen J, Li Z, Zhang Z, Yu H, Sun K, Wang X, Song X, Wang Y, Zhen Y, Yang T, Lou K, Zhang Y, Zhang G, Hu Y, Ji J, Hui R.

Oncogene. 2011 Sep 29;30(39):4107-17. doi: 10.1038/onc.2011.116.

PMID:
21499297
16.

In vitro and in vivo inhibitory effect of the combination of Wenxia Changfu formula [see text] with cisplatin in non-small cell lung cancer.

Ji XM, Ouyang B, Liu H, Liu GW, Wu ZC, Yu HY, Wang CY, Wang ZX, Wang WP.

Chin J Integr Med. 2011 Dec;17(12):908-16. doi: 10.1007/s11655-011-0933-6.

PMID:
22139542
17.

Cancer-testis antigen BORIS is a novel prognostic marker for patients with esophageal cancer.

Okabayashi K, Fujita T, Miyazaki J, Okada T, Iwata T, Hirao N, Noji S, Tsukamoto N, Goshima N, Hasegawa H, Takeuchi H, Ueda M, Kitagawa Y, Kawakami Y.

Cancer Sci. 2012 Sep;103(9):1617-24. doi: 10.1111/j.1349-7006.2012.02355.x.

18.
19.

In vitro and in vivo anti-tumor effect of metformin as a novel therapeutic agent in human oral squamous cell carcinoma.

Luo Q, Hu D, Hu S, Yan M, Sun Z, Chen F.

BMC Cancer. 2012 Nov 14;12:517. doi: 10.1186/1471-2407-12-517.

20.

Cell cycle protein cyclin Y is associated with human non-small-cell lung cancer proliferation and tumorigenesis.

Yue W, Zhao X, Zhang L, Xu S, Liu Z, Ma L, Jia W, Qian Z, Zhang C, Wang Y, Yang X.

Clin Lung Cancer. 2011 Jan;12(1):43-50. doi: 10.3816/CLC.2011.n.006.

PMID:
21273179
Items per page

Supplemental Content

Support Center